Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2098979 | 1.00 | CXCR4 (0.46) | CXCR4HRH3ALDH1A1KDM4E | |
| SCHEMBL2099968 | 1.00 | CXCR4 (0.46) | CXCR4HRH3ALDH1A1KDM4E | |
| SCHEMBL2100958 | 0.98 | CXCR4 (0.45) | CXCR4HRH3ALDH1A1KDM4E | |
| SCHEMBL2100067 | 0.98 | CXCR4 (0.45) | CXCR4HRH3ALDH1A1KDM4E | |
| SCHEMBL736496 | 0.93 | — | — | |
| SCHEMBL738621 | 0.93 | — | — | |
| SCHEMBL771157 | 0.93 | — | — | |
| SCHEMBL3080548 | 0.88 | CXCR4 (0.51) | CXCR4HRH3ALDH1A1 | |
| SCHEMBL18768683 | 0.86 | CXCR4 (0.51) | CXCR4HRH3ALDH1A1 | |
| SCHEMBL23828678 | 0.84 | CXCR4 (0.50) | CXCR4HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4664597-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| EP-1511734-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2010-06-23 | — | — | EP | claimed |
| EP-1786265-A4 | NOVEL COMPOSITIONS AND METHODS OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2009-08-19 | — | — | EP | claimed |
| CN-101500994-A | 1,3-disubstituted 4-methyl-1h-pyrrole-2-carboxamides and their use for the manufacture of medicaments | GRUENENTHAL CHEMIE (DE) | 2009-08-05 | — | — | CN | claimed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | claimed |
| WO-2008153701-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | claimed |
| EP-1692112-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-09-24 | — | — | EP | claimed |
| CN-101103023-A | Disubstituted ureas as kinase inhibitors | NOVARTIS AG (CH) | 2008-01-09 | — | — | CN | claimed |
| US-20070207996-A1 | Novel Compositions And Methods Of Treatment | CYTOKINETICS, INCORPORATED | 2007-09-06 | — | — | US | claimed |
| EP-1594849-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2001098278-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| EP-1150565-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION bioscience AG (DE) | 2001-11-07 | — | — | EP | claimed |
| WO-2001030768-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-05-03 | — | — | WO | claimed |
| WO-2001025203-A1 | PYRIDINE CARBOXAMIDE OR SULFONAMIDE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-04-12 | — | — | WO | claimed |
| WO-2001023887-A1 | 2-AMINOPYRIDINE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-04-05 | — | — | WO | claimed |
| WO-2000069849-A1 | PYRAZOLE CARBOXAMIDES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-11-23 | — | — | WO | claimed |
| WO-2000045635-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2000-08-10 | — | — | WO | claimed |
| WO-1999009845-A1 | IMIDAZOQUINOXALINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-04 | — | — | WO | claimed |
| US-5668165-A | TREATMENT OF HIV INFECTIONS | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 1997-09-16 | — | — | US | claimed |
| US-4624698-A | Herbicidal tetrahydrobenzothiazolyl-1,3,5-triazinone derivatives and compositions thereof | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1986-11-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207996-A1 | Novel Compositions And Methods Of Treatment | KIF5B, KIF5C, PLK1 | CXCR4 3842/4885HRH3 3031/4885ALDH1A1 3671/4885 |
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | CXCR4 3728/4885HRH3 3854/4885ALDH1A1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.